Anti-ADM Antibody Therapy for Shock Circulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for shock, particularly septic shock, often require multiple medications and have challenges in optimizing the timing of anti-adrenomedullin (ADM) antibody administration to achieve optimal benefits, with existing treatments sometimes being detrimental due to the complex physiological effects of ADM and the need for balancing its activity levels.
Innovation Solution
Development of an anti-ADM antibody or fragment, or non-Ig scaffold that binds specifically to ADM, administered at optimal timing post-shock or ICU admission, particularly when DPP3 levels in bodily fluids are below a threshold, to stabilize circulation and reduce vasopressor requirements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-ADM antibody is administered to stabilize circulation in shock patients, then circulation stability improves and vasopressor requirements reduce, but the complexity of timing optimization and DPP3 level monitoring increases
Solution Approach 1:
The patent employs feedback mechanisms by monitoring DPP3 levels in bodily fluids to determine optimal timing for anti-ADM antibody administration. The therapy is activated when DPP3 levels fall below a predefined threshold, creating a closed-loop control system that adapts to patient condition changes and optimizes treatment timing dynamically.
Solution Approach 2:
The system uses the patient's own DPP3 level as a self-diagnostic marker to trigger therapy initiation. This self-service approach eliminates the need for complex external monitoring systems, allowing the patient's physiological state to automatically guide treatment timing through objective biomarker measurement.
2Ease of operation
If multiple medications are used to treat shock symptoms, then symptom alleviation improves, but the complexity of coordinating multiple drugs and optimizing timing increases
Solution Approach 1:
The anti-ADM antibody serves multiple functions simultaneously: it stabilizes circulation, reduces vasopressor requirements, and acts as a timing indicator through DPP3 level monitoring. This multi-functionality consolidates what would otherwise require multiple separate medications and monitoring systems into a single therapeutic agent with broad applicability.
Solution Approach 2:
The patent merges the therapeutic effect of ADM inhibition with the diagnostic function of DPP3 level monitoring into a unified treatment strategy. By combining these functions, the system reduces the need for separate diagnostic and therapeutic interventions, simplifying overall treatment coordination.
3Reliability
If ADM activity levels are increased to improve circulation, then circulation stability improves, but harmful physiological effects increase
Solution Approach 1:
The patent changes the parameter of ADM activity levels dynamically based on DPP3 monitoring. By adjusting the timing and dosage of anti-ADM antibody administration according to real-time DPP3 levels, the system optimizes ADM activity to achieve circulation stability while minimizing harmful effects through precise parameter control.
Solution Approach 2:
The therapy applies partial action by administering anti-ADM antibody only when DPP3 levels indicate specific physiological conditions, rather than continuously or excessively. This targeted approach ensures sufficient ADM inhibition for circulation stability while avoiding excessive action that would cause harmful physiological effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-ADM antibody or fragment effectively stabilizes circulation, reduces the need for vasopressors, and improves patient outcomes by prolonging ADM's half-life and maintaining beneficial ADM activity levels, thereby enhancing survival rates and fluid balance in shock patients.
Implementation Method 1
an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold binds specifically to ADM
Data Source
AI summary
Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of patients in shock and/or for use in therapy of diseases which necessitates admission of the patients to ICU.